Format

Send to

Choose Destination
Schizophr Res. 2014 Feb;152(2-3):450-7. doi: 10.1016/j.schres.2013.11.041. Epub 2014 Jan 10.

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.

Author information

1
Forest Research Institute, Harborside Financial Center, Plaza V, Jersey City, NJ, USA. Electronic address: suresh.durgam@frx.com.
2
Forest Research Institute, Harborside Financial Center, Plaza V, Jersey City, NJ, USA. Electronic address: anju.starace@frx.com.
3
Forest Research Institute, Harborside Financial Center, Plaza V, Jersey City, NJ, USA. Electronic address: dayong.li@frx.com.
4
Forest Research Institute, Harborside Financial Center, Plaza V, Jersey City, NJ, USA. Electronic address: raffaele.migliore@frx.com.
5
Prescott Medical Communications Group, 205 N. Michigan Ave, Suite 3400, Chicago, IL, USA. Electronic address: aruth@prescottmed.com.
6
Gedeon Richter Plc, H-1103 Budapest 10, Gyomroi u. 19-21, Hungary. Electronic address: gy.nemeth@richter.hu.
7
Gedeon Richter Plc, H-1103 Budapest 10, Gyomroi u. 19-21, Hungary. Electronic address: i.laszlovszky@richter.hu.

Abstract

INTRODUCTION:

Cariprazine is an orally active and potent D3 and D2 partial agonist with preferential binding to D3 receptors in development for the treatment of schizophrenia and bipolar mania. This study (NCT00694707) evaluated the efficacy and safety of cariprazine in patients with acute exacerbation of schizophrenia.

METHODS:

This study was a multinational, double-blind, randomized, placebo- and active-controlled, fixed-dose trial. Patients were randomized to receive placebo, cariprazine 1.5mg/d, cariprazine 3.0mg/d, cariprazine 4.5mg/d, or risperidone 4.0mg/d (for assay sensitivity) for 6 weeks of double-blind treatment and 2 weeks of safety follow-up. Primary and secondary efficacy parameters were change from baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) total and Global Impressions-Severity of Illness (CGI-S) scores, respectively. Safety parameters included adverse events (AEs), vital signs, laboratory measures, and extrapyramidal symptom (EPS) scales.

RESULTS:

Of 732 randomized patients, 64% completed the study. PANSS total score improvement at Week 6 was statistically significant versus placebo for cariprazine 1.5mg/d, 3.0mg/d, and 4.5mg/d (least squares mean difference [LSMD]: -7.6, -8.8, -10.4, respectively; p<0.001; LOCF) and risperidone (-15.1, p<0.001; LOCF); significant improvement on CGI-S was demonstrated for all active treatments (p<0.05). The most frequent cariprazine AEs (≥ 5% and at least twice the rate of the placebo group) were insomnia, extrapyramidal disorder, akathisia, sedation, nausea, dizziness, and constipation. Mean changes in metabolic parameters were small and similar between groups.

CONCLUSION:

The results of this study support the efficacy and safety of cariprazine in patients with acute exacerbation of schizophrenia.

KEYWORDS:

Antipsychotic; Cariprazine; D(3); Dopamine; Schizophrenia

PMID:
24412468
DOI:
10.1016/j.schres.2013.11.041
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center